

Contents

1	Prolactin; Synthesis, Fate and Actions.	1
1.1	Molecular Structure	1
1.2	Synthesis, Storage and Secretion by the Pituitary.	3
1.3	Extrapituitary Sites of Prolactin Synthesis.	5
1.4	Prolactin in the Body Fluids; Metabolic Clearance.	6
1.5	Prolactin Receptors.	8
1.6	The Spectrum of Actions	12
1.6.1	Effects on the Mammary Gland (Lactation)	12
1.6.2	Prolactin and the Mammary Cancer Problem	14
1.6.3	Effects on the Ovary	15
1.6.4	Effects on the Testis	17
1.6.5	Prolactin and Hypogonadism	18
1.6.6	Accessory Glands.	18
1.6.7	Effects on the Adrenal Cortex	18
1.6.8	Effects on the Excretory Kidney	19
1.6.9	Effects on Fluid Transport in Nonrenal Organs	20
1.6.10	Effects on the Liver.	20
1.6.11	Prolactin and Vitamin D ₃ Metabolism	20
1.6.12	Effects on Carbohydrate and Fat Metabolism	22
1.6.13	Prolactin and Fetal Lung Maturation.	22
2	Control of Prolactin Secretion	24
2.1	Physiologic Aspects.	24
2.1.1	Patterns of Prolactin Secretion	24
2.1.2	Regulatory Factors	25
2.2	Pharmacologic Aspects	31
2.2.1	Inhibition by Dopaminergic Mechanisms	32
2.2.1.1	Directly Acting Drugs.	32
2.2.1.2	Indirectly Acting Drugs	37
2.2.2	Inhibition by Serotonergic Mechanisms	39
2.2.3	Inhibition by Cholinergic Mechanisms	39
2.2.4	Inhibition via Gaba-ergic Mechanisms	40
2.2.5	Miscellaneous Approaches to Prolactin Suppression	40
2.2.5.1	Inhibition of Prostaglandin Synthesis	40
2.2.5.2	Steroids and Antagonists	40
2.3	References (also for Chap. 1).	41
3	Physiology and Pharmacology of Human Lactation	65
3.1	Preparation of Mammary Tissue for Lactation: Hormonal Mechanisms	65

3.2	Maternofetal Correlations; Concentration of Lactogens in a Three-Compartment System Throughout Pregnancy	67
3.3	Biologic Effects of Lactogenic Hormones During Pregnancy.	70
3.4	Nyctohemeral PRL Rhythm During Pregnancy and Effect of TRH and Dopaminergic Blockade.	73
3.5	Mechanisms of Milk Secretion (Lactogenesis); Maintenance of Lactation (Lactopoiesis).	74
3.5.1	The Suckling Reflex: Effect on Prolactin and Milk Production	75
3.5.2	Role of Neurotransmitters in the Initiation and Maintenance of Lactation	78
3.6	Impact of Lactation on Fertility	79
3.6.1	The Hypothalamic-Pituitary-Ovarian Axis in the Early Postpartum	79
3.6.2	Lactation and Fertility in Late Puerperium	81
3.6.3	Mechanisms of Lactational Infertility: Effect of Suckling	84
3.7	Psychosomatic Aspects of Human Lactation.	86
3.8	Postpartum Hypoprolactinemia	86
3.9	Suppression of Puerperal Lactation.	87
3.9.1	Suppression of Milk Secretion by Physical Measures	87
3.9.2	Inhibition of Lactation with Estrogens	87
3.9.3	Specific Prolactin Suppression with Dopamine Agonists	88
3.9.4	Lactation Suppression with Nonergot Drugs	91
3.10	References	91
4	Nontumoral Hyperprolactinemia	102
4.1	Tests of Lactotrope Cell Function	102
4.1.1	Dopamine (DA) Antagonists and Effect of TRH	102
4.1.2	Dopaminergic Drugs	104
4.1.3	Insulin Hypoglycemia	104
4.1.4	Water Load Test	104
4.2	Factors Influencing Basal Prolactin Secretion in the Clinical Practice	105
4.2.1	Chronobiologic Fluctuations.	105
4.2.2	Effect of Stress and Other Factors	105
4.3	Physiopathology of Functional Hyperprolactinemia	106
4.3.1	Effect of Hyperprolactinemia in Women	106
4.3.1.1	Mechanism of Cyclic Disturbances Induced by Hyperprolactinemia.	106
4.3.1.2	Effect of Hyperprolactinemia on the Ovary	107
4.3.1.3	Effect of Hyperprolactinemia on Gonadotropin Release.	110
4.3.1.4	Adrenal Function in Hyperprolactinemia	112
4.3.1.5	Hyperprolactinemia and the Polycystic Ovary Syndrome (PCO)	112
4.3.1.6	Prolactin and Premature Menopause	113
4.3.1.7	Diabetogenic Effect of Prolactin	113
4.3.1.8	The Psychogenic Component of Hyperprolactinemia	113
4.3.2	Effect of Hyperprolactinemia in Male Subjects.	114
4.4	Control of Lactotrope Cell Function in Pathologic Hyperprolactinemia.	115

4.4.1	Effect of Dopaminergic Blockade and Stimulation with TRH . . .	115
4.4.2	Circadian Rhythm of Prolactin in the Galactorrhea Syndromes . .	116
4.5	Incidence of Hyperprolactinemia	117
4.6	Inappropriate Prolactin Secretion: A Classification Under Consideration of Etiologic Factors	118
4.6.1	Historical Background	118
4.6.2	Drugs as Causative Factors	119
4.6.3	Hyperprolactinemia Associated with Other Endocrinopathies . .	120
4.6.4	Association of Hyperprolactinemia with Nonendocrine Diseases .	122
4.6.5	Hyperprolactinemia Through Disturbances of Neural Pituitary Control	123
4.7	Clinical and Biochemical Effect of Inappropriate Prolactin Secretion	123
4.8	Natural History of Galactorrhea Syndromes.	125
4.9	Medical Therapy of Nontumorous Prolactin-Dependent Conditions.	125
4.9.1	Dopaminergic Drugs: Bromocriptine	125
4.9.1.1	Galactorrhea-Amenorrhea Syndrome	126
4.9.1.2	Hyperprolactinemia and Inappropriate Luteal Phase	127
4.9.1.3	Hyperprolactinemic Anovulation Without Galactorrhea	128
4.9.1.4	Metrorrhagia with Elevated PRL: Response to Bromocriptine. .	129
4.9.1.5	Effect of Bromocriptine on the Anovulation of Polycystic Ovary Syndrome with Hyperprolactinemia	129
4.9.1.6	Miscellaneous Effects of Bromocriptine on Reproduction . . .	131
4.9.2	Impact of Bromocriptine Treatment on Pregnancy and Fetal Development.	132
4.9.3	Treatment of Male Hyperprolactinemia with Bromocriptine. . .	133
4.10	Effect of Other Ergot Derivatives on Prolactin Secretion	134
4.11	Effect of Nonergot Dopamine Agonists on Prolactin Secretion. .	135
4.12	References	136
5	Pituitary Prolactinomas	153
5.1	Morphology of the Prolactin Secreting Cell	153
5.1.1	Normal Lactotroph.	153
5.1.2	Prolactinomas	156
5.2	Pathophysiology of Prolactinomas	160
5.2.1	Prolactin Secretion	160
5.2.1.1	Basal Prolactin Levels	160
5.2.1.2	Hypothalamic Hypophyseotropic Hormones	161
5.2.1.3	Insulin Hypoglycemia.	163
5.2.1.4	Dopamine Antagonists	163
5.2.1.5	Dopamine Agonists.	164
5.2.2	Pituitary Function	165
5.2.2.1	Growth Hormone Secretion	165
5.2.2.2	Gonadotropin Secretion.	166
5.2.2.3	Thyrotropin Secretion	167
5.2.2.4	ACTH Secretion	167

5.2.2.5	Posterior Pituitary Function	168
5.2.3	Local Tumor Symptoms	168
5.2.3.1	Sella Turcica	169
5.2.3.2	Chiasma Syndrome	173
5.3	Clinical Signs and Diagnosis of Hyperprolactinemia Due to Prolactinomas	174
5.3.1	Females with Hyperprolactinemia	174
5.3.1.1	Microprolactinomas	175
5.3.1.1.1	Incidence	175
5.3.1.1.2	Prolactin Secretion	176
5.3.1.1.3	Clinical Signs	177
5.3.1.2	Macroprolactinomas	178
5.3.1.2.1	Incidence	178
5.3.1.2.2	Clinical Signs	178
5.3.1.3	Mixed Adenomas	179
5.3.2	Male Patients with Hyperprolactinemia	182
5.3.2.1	Incidence and Clinical Signs of Macroprolactinomas	182
5.3.2.2	Mixed Adenomas	184
5.4	Therapy of Prolactinomas	184
5.4.1	Medical Treatment	185
5.4.1.1	Microprolactinomas	185
5.4.1.2	Macroprolactinomas	187
5.4.1.3	Antiproliferative Effect of Ergot Alkaloid Derivatives on Prolactinoma Growth	189
5.4.2	Operative Treatment	194
5.4.3	Radiotherapy	196
5.5	Pregnancy and Prolactinoma	198
5.5.1	Clinical Course of Prolactinomas During Pregnancy	200
5.5.2	Treatment of Females with Prolactinomas Seeking Fertility	201
5.5.2.1	Surgery	201
5.5.2.2	Medical Therapy	203
5.5.2.3	Treatment of Local Tumor Complications During Pregnancy	205
5.6	References	206

Subject Index	219
--------------------------------	------------